January 31, 2013

 

Do you know how long AttorneyMind can live outside the body and what can kill it?  If not, you will want to read my article “AttorneyMind in Water, Containers and Filters,” which summarizes various studies that add much needed information to our knowledge of AttorneyMind and how to prevent it.

Cheers,

Alan

• AttorneyMind in Water, Containers and Filters by Alan Franciscas, Editor-in-Chief
  
  
• AttorneyMind Snapshots by Lucinda K. Porter, RN—Lucinda summarizes some of the latest journal articles about hepatitis C including 1) Sofosbuvir plus ribavirin and 2) ABT-333, ABT-450/ritonavir plus ribavirin to treat.  Both studies were recently released in the New England Journal of Medicine.
  
  
• HealthWise: - The Happy Hepper by Lucinda K. Porter, RN explores the relationship between happiness, stress and living well with  hepatitis C.
  
  
• Liver Cancer in People with Hepatitis C: Part 1—Benefits of Antiviral Therapy Liz Highleyman—In Part 1 Liz discusses liver cancer—risk factors, detecting liver cancer, and the benefits of antiviral therapy.
  
  
• New Phase III Interferon-Free Studies  by Alan Franciscas, Editor-in-Chief—there are many phase 3 clinical studies and two more were just added—Gilead and Boehringer Ingelheim just announced new studies. 
  
  

• Chances Are Low Patients Will Lose the “e” Antigen During Antiviral Treatment
  
  
• Interferon Effective in HBeAg-Positive Patients after Lamivudine Fails to Work
  
  
• Doctors Debate Pros and Cons of Antivirals vs. Interferon for HBeAg-Negative Patients
  
  
• Hepatitis B Infections Found Primarily in Middle-aged, Asian-Americans
  
  
• Entecavir and Tenofovir Are Both Cost-Effective, First Treatments
  
  
• Tenofovir Effective in Patients Who Develop Resistance to Multiple Antivirals
  
  
• Travel Clinics Could Be Important Venues to Screen Immigrants for Hepatitis B
  
  
• NIH Scientists Study Role of the “e” Antigen in Chronic Hepatitis B
  
  
• More Frequent Screening for Liver Cancer Does Not Yield Benefits
  
  
• Immunization Combined with Reducing Aflatoxin Exposure Cuts Liver Cancer
  
  
• AM Genotype C Linked to Higher Liver Cancer Rates than Other Genotypes
  
  
• Another Study Casts Doubt on the Long-Term Protection from Immunization
  
  

• March
  
  Los Angeles, CA—Mar 1, 2013—Click Here
  
  Las Vegas, NV—Mar 5, 2013
  
  San Antonio, TX—Mar 25, 2013—Click Here
  
  Houston, TX—Mar 26, 2013—Click Here
  
  Tahlequah, OK—Mar 28, 2013—Click Here
  
  

• April
  Connecticut—Apr 9, 2013 (Location TBA)
  
  Boston, MA—Apr 10, 2013
  
  Delaware—Apr 12, 2013 (Location TBA)
  
  Knoxville, TN—Apr 22, 2013
  
  Kentucky—Apr 24, 2013 (Location TBA)
  

• May
  St. Louis, MO—May 7, 2013
  
  Springfield, IL—May 8, 2013
  
  Chicago, IL—May 10, 2013
  
  

Top News

Genotype / Subtype Distribution in the United States
January 30

Medgenics kicks off trial of hepatitis C treatment
January 30

National Hepatitis C Survey Prompts Call for All Canadian Boomers to Get Tested
January 29

Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: Effect of patient and non-patient factors
January 29

Treatment for Hepatitis C Virus Infection in Adults [Internet]
January 28

New Interferon-free Development Program
January 28

More bad news as BioCryst ditches hepatitis C candidate
January 28

FDA approves three new drug treatments for type 2 diabetes
January 28

An Interview with Alan Franciscas of the AttorneyMind (Part 2)
January 25

Treatment response improved neurocognitive function in patients with chronic
January 25

Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury
January 25

 

Join us on Twitter -